A new study presented at this year’s American College of Allergy, Asthma and Immunology Annual Scientific Meeting highlights the need for mental health support in patients with atopic dermatitis (AD).
This article was originally published by Dermatology Times®. It has been lightly edited.
Almost three-quarters of patients with atopic dermatitis (AD) experience mental health distress associated with their health condition, according to a new study presented at this year’s American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting.1
Allison Loiselle, PhD, of the National Eczema Association, and colleagues recruited adults aged 18 and older with AD, as well as caregivers of youth patients aged 8 to 17 years old from October through November 2022. A total of 954 participants completed an online survey to share their experiences.
According to the study results, mental health concerns are prevalent in patients with AD, yet they may not be communicating this with clinicians. Specifically, 72.6% of patients experienced poor mental health symptoms for 1 to 10 days within the preceding month.
About one-fifth of participants (17.7%) indicated a more chronic nature of their mental health symptoms, with symptoms lasting more than 11 days. Less than one-half of patients (42.5%) had been asked about their mental health by their clinician, and about one-third of the respondents noted they did not disclose their symptoms with their clinicians. Consequently, less than half of the patients (45.1%) received referrals for mental health care services or other supports.
This study supports recent research exploring the link between patients' mental health, well-being, and AD. Earlier this year, the results of a comprehensive literature search on improving psychological health outcomes in children found psychological well-being was directly related to objective disease severity. Furthermore, the researchers noted improvements in psychological well-being were directly correlated with improvements in disease severity.2
Fortunately, behavioral interventions can also improve both the itch-scratch cycle as well as the psychological sequelae associated with AD. There is evidence that hypnotherapy, biofeedback, and mindfulness therapy can support patients and result in improvements.
“People who don’t suffer with AD don’t understand how debilitating it can be,” Loiselle said in a press statement.3 “In addition to the terrible itching and dry, cracked skin, there are often sleep disruptions, and broader impacts on quality of life and overall well-being. Depression and anxiety are among the symptoms of those who deal with AD and the chronic, unpredictable nature of this condition.”
Tamara Hubbard, MA, LCPC, explained in a press statement that “AD-related quality of life impacts can include social impairment, emotional and behavioral problems, and significant psychological problems, including depression, anxiety, and suicidal ideation." Hubbard works with parents of children with allergies and added that the “relentless itching” and AD’s negative effects on appearance can also take a toll on patients.
“It’s important for patients and health care providers to discuss mental health concerns and to be aware of resources and trained mental health professionals who can help," Hubbard said.
References
1. Loiselle A, Johnson J, Begolka WS. Atopic dermatitis patient experience with discussing and addressing mental health concerns with allergists. Poster presented at: 2023 ACAAI Annual Scientific Meeting; November 9-13, 2023; Anaheim, California.
2. Mostafa N, Smith SD. Improving psychological health outcomes in children with atopic dermatitis. Clin Cosmet Investig Dermatol. 2023;16:2821-2827. doi:10.2147/CCID.S393254
3. Survey: 72% of eczema patients suffered poor mental health symptoms for 1-10 days in past month. News release. ACAAI; November 9, 2023.
Diagnostic Oversights Limit Luspatercept Benefits in MDS
May 8th 2024Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Coexistence of HIV, Hemophilia May Lead to Increased Presence of Coronary Artery Stenosis
May 8th 2024In patients living with HIV, the cardiovascular risk factors that come with infection may lead to an increased prevalence of coronary artery stenosis, especially in those who also have hemophilia.
Read More